Global Homozygous Familial Hypercholesterolemia (HoFH) Pipeline Review 2016 - 5 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Homozygous Familial Hypercholesterolemia (HoFH) Overview
  3. Therapeutics Development
  4. Pipeline Products for Homozygous Familial Hypercholesterolemia (HoFH) - Overview
  5. Pipeline Products for Homozygous Familial Hypercholesterolemia (HoFH) - Comparative Analysis
  6. Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics under Development by Companies
  7. Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics under Investigation by Universities/Institutes
  8. Homozygous Familial Hypercholesterolemia (HoFH) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Homozygous Familial Hypercholesterolemia (HoFH) - Products under Development by Companies
  13. Homozygous Familial Hypercholesterolemia (HoFH) - Products under Investigation by Universities/Institutes
  14. Homozygous Familial Hypercholesterolemia (HoFH) - Companies Involved in Therapeutics Development
  • Aegerion Pharmaceuticals, Inc.
  • CymaBay Therapeutics, Inc.
  • Kastle Therapeutics LLC
  • Regeneron Pharmaceuticals, Inc.
  • RegenxBio Inc.

For more information visit http://www.researchandmarkets.com/research/z93327/homozygous

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular Drugs